Andres Henao Martinez
Concepts (492)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Chagas Disease | 13 | 2023 | 33 | 7.260 |
Why?
| Chagas Cardiomyopathy | 7 | 2023 | 21 | 4.390 |
Why?
| Meningitis, Cryptococcal | 8 | 2024 | 29 | 3.680 |
Why?
| Cryptococcosis | 6 | 2023 | 25 | 3.440 |
Why?
| Opportunistic Infections | 4 | 2024 | 46 | 2.630 |
Why?
| Trypanosoma cruzi | 6 | 2023 | 24 | 2.430 |
Why?
| Cryptococcus neoformans | 4 | 2024 | 19 | 1.870 |
Why?
| Invasive Pulmonary Aspergillosis | 2 | 2023 | 5 | 1.720 |
Why?
| HIV Infections | 10 | 2024 | 2703 | 1.640 |
Why?
| Travel | 6 | 2021 | 121 | 1.620 |
Why?
| Strongyloidiasis | 2 | 2024 | 4 | 1.430 |
Why?
| Cryptococcus | 2 | 2024 | 7 | 1.430 |
Why?
| Immunocompromised Host | 6 | 2024 | 195 | 1.340 |
Why?
| Stroke, Lacunar | 2 | 2019 | 4 | 1.270 |
Why?
| Anti-Bacterial Agents | 9 | 2025 | 1689 | 1.190 |
Why?
| Tuberculosis | 2 | 2022 | 271 | 1.170 |
Why?
| Transients and Migrants | 3 | 2023 | 25 | 1.170 |
Why?
| Candidemia | 2 | 2024 | 8 | 1.160 |
Why?
| Humans | 104 | 2025 | 128020 | 1.160 |
Why?
| Hospitalization | 7 | 2024 | 2057 | 1.120 |
Why?
| Cardiomyopathies | 2 | 2021 | 335 | 1.100 |
Why?
| Yellow Fever | 3 | 2022 | 7 | 1.080 |
Why?
| Bacteremia | 5 | 2023 | 192 | 1.030 |
Why?
| Infectious Disease Transmission, Vertical | 2 | 2019 | 170 | 1.010 |
Why?
| Candida | 2 | 2024 | 35 | 0.990 |
Why?
| Glucocorticoids | 3 | 2024 | 572 | 0.970 |
Why?
| Antifungal Agents | 8 | 2023 | 128 | 0.970 |
Why?
| Central Nervous System Neoplasms | 2 | 2018 | 148 | 0.960 |
Why?
| Adult | 37 | 2025 | 35177 | 0.920 |
Why?
| Macrolides | 1 | 2025 | 62 | 0.920 |
Why?
| Parasitemia | 2 | 2015 | 11 | 0.910 |
Why?
| Pneumocystis | 1 | 2024 | 11 | 0.900 |
Why?
| Risk Factors | 15 | 2024 | 9696 | 0.890 |
Why?
| Mycoses | 1 | 2024 | 70 | 0.890 |
Why?
| Pneumonia, Pneumocystis | 1 | 2024 | 34 | 0.890 |
Why?
| Drug Hypersensitivity | 1 | 2025 | 81 | 0.870 |
Why?
| Pulmonary Aspergillosis | 1 | 2023 | 3 | 0.870 |
Why?
| Nitroimidazoles | 1 | 2023 | 9 | 0.870 |
Why?
| Pneumonia, Viral | 7 | 2020 | 337 | 0.850 |
Why?
| Coronavirus Infections | 7 | 2020 | 333 | 0.840 |
Why?
| Myocarditis | 2 | 2016 | 98 | 0.840 |
Why?
| Anemia, Aplastic | 1 | 2023 | 35 | 0.840 |
Why?
| AIDS-Related Opportunistic Infections | 1 | 2024 | 123 | 0.830 |
Why?
| Male | 45 | 2025 | 62758 | 0.820 |
Why?
| Enterobacteriaceae Infections | 2 | 2013 | 37 | 0.810 |
Why?
| Zoonoses | 2 | 2024 | 27 | 0.800 |
Why?
| Virus Diseases | 1 | 2024 | 209 | 0.780 |
Why?
| Antigens, Fungal | 2 | 2024 | 27 | 0.750 |
Why?
| Immunotherapy, Adoptive | 1 | 2024 | 295 | 0.740 |
Why?
| Neglected Diseases | 1 | 2020 | 4 | 0.720 |
Why?
| Mycobacterium Infections | 2 | 2018 | 61 | 0.710 |
Why?
| Hepatitis | 1 | 2020 | 47 | 0.700 |
Why?
| Middle Aged | 24 | 2025 | 30813 | 0.680 |
Why?
| Hantavirus Pulmonary Syndrome | 1 | 2020 | 3 | 0.680 |
Why?
| Heart Aneurysm | 1 | 2019 | 10 | 0.670 |
Why?
| Epidemics | 1 | 2020 | 82 | 0.650 |
Why?
| Massive Hepatic Necrosis | 1 | 2019 | 3 | 0.650 |
Why?
| Aneurysm, False | 1 | 2019 | 48 | 0.640 |
Why?
| United States | 19 | 2024 | 13785 | 0.640 |
Why?
| Hepatitis A | 1 | 2019 | 25 | 0.640 |
Why?
| Leukemia, Myelomonocytic, Chronic | 1 | 2018 | 2 | 0.620 |
Why?
| Neisseria gonorrhoeae | 1 | 2019 | 24 | 0.620 |
Why?
| Sarcoma, Myeloid | 1 | 2018 | 4 | 0.620 |
Why?
| Hematoma, Subdural | 1 | 2018 | 17 | 0.620 |
Why?
| Female | 36 | 2025 | 68017 | 0.590 |
Why?
| Plasmodium falciparum | 1 | 2018 | 29 | 0.590 |
Why?
| Malaria, Falciparum | 1 | 2018 | 26 | 0.590 |
Why?
| Skin | 3 | 2022 | 711 | 0.590 |
Why?
| Gonorrhea | 1 | 2019 | 57 | 0.590 |
Why?
| Fever | 2 | 2020 | 295 | 0.590 |
Why?
| Chromoblastomycosis | 1 | 2017 | 1 | 0.580 |
Why?
| Hand Dermatoses | 1 | 2017 | 7 | 0.580 |
Why?
| Renal Insufficiency | 1 | 2020 | 148 | 0.580 |
Why?
| Population Groups | 1 | 2018 | 58 | 0.580 |
Why?
| Dyspnea | 1 | 2019 | 238 | 0.570 |
Why?
| Delayed Diagnosis | 1 | 2018 | 79 | 0.570 |
Why?
| Meningioma | 1 | 2018 | 80 | 0.570 |
Why?
| Meningeal Neoplasms | 1 | 2018 | 93 | 0.570 |
Why?
| Medically Uninsured | 1 | 2018 | 127 | 0.560 |
Why?
| Abscess | 1 | 2018 | 73 | 0.560 |
Why?
| Milk | 1 | 2018 | 119 | 0.550 |
Why?
| Heart Failure | 2 | 2022 | 2141 | 0.550 |
Why?
| Pandemics | 10 | 2023 | 1473 | 0.540 |
Why?
| Retrospective Studies | 12 | 2024 | 14404 | 0.540 |
Why?
| Osteomyelitis | 1 | 2019 | 123 | 0.540 |
Why?
| Latin America | 6 | 2022 | 86 | 0.530 |
Why?
| Poliomyelitis | 3 | 2022 | 36 | 0.530 |
Why?
| Trichuriasis | 1 | 2016 | 4 | 0.520 |
Why?
| Prisons | 4 | 2021 | 79 | 0.520 |
Why?
| Pregnancy Complications, Parasitic | 1 | 2016 | 9 | 0.520 |
Why?
| Lymphocytosis | 1 | 2016 | 10 | 0.520 |
Why?
| Neoplasms, Unknown Primary | 1 | 2016 | 13 | 0.520 |
Why?
| Pregnancy Complications, Hematologic | 1 | 2016 | 18 | 0.520 |
Why?
| Enterobacteriaceae | 2 | 2013 | 35 | 0.520 |
Why?
| Parotid Neoplasms | 1 | 2016 | 16 | 0.520 |
Why?
| Occupational Diseases | 1 | 2017 | 138 | 0.510 |
Why?
| Diphyllobothriasis | 1 | 2015 | 2 | 0.500 |
Why?
| Diphyllobothrium | 1 | 2015 | 2 | 0.500 |
Why?
| Colombia | 4 | 2020 | 36 | 0.500 |
Why?
| Plasmablastic Lymphoma | 1 | 2015 | 7 | 0.500 |
Why?
| Insect Vectors | 1 | 2015 | 27 | 0.490 |
Why?
| Pre-Exposure Prophylaxis | 1 | 2018 | 202 | 0.490 |
Why?
| Gamma Rays | 1 | 2015 | 53 | 0.490 |
Why?
| Plasma Cells | 1 | 2015 | 65 | 0.480 |
Why?
| Transplants | 1 | 2015 | 35 | 0.480 |
Why?
| Lymphoma | 1 | 2016 | 194 | 0.470 |
Why?
| Anemia | 1 | 2016 | 160 | 0.460 |
Why?
| Bone Marrow | 1 | 2016 | 267 | 0.460 |
Why?
| Heart Ventricles | 1 | 2019 | 765 | 0.460 |
Why?
| Proto-Oncogene Proteins c-akt | 2 | 2023 | 419 | 0.450 |
Why?
| Thrombocytopenia | 1 | 2016 | 184 | 0.440 |
Why?
| Environmental Exposure | 1 | 2018 | 458 | 0.430 |
Why?
| Transplant Recipients | 1 | 2015 | 152 | 0.430 |
Why?
| Aged | 12 | 2024 | 21892 | 0.430 |
Why?
| Research | 1 | 2016 | 408 | 0.420 |
Why?
| Betacoronavirus | 6 | 2020 | 247 | 0.420 |
Why?
| Myocardial Contraction | 1 | 2015 | 333 | 0.420 |
Why?
| Lymphoma, Primary Effusion | 1 | 2013 | 3 | 0.420 |
Why?
| Thrombocytosis | 1 | 2013 | 6 | 0.420 |
Why?
| Lymphoma, AIDS-Related | 1 | 2013 | 14 | 0.410 |
Why?
| Methicillin-Resistant Staphylococcus aureus | 4 | 2023 | 215 | 0.400 |
Why?
| Herpesvirus 8, Human | 1 | 2013 | 59 | 0.400 |
Why?
| Antigens, Protozoan | 1 | 2012 | 22 | 0.400 |
Why?
| Acinetobacter Infections | 1 | 2012 | 10 | 0.400 |
Why?
| Acinetobacter | 1 | 2012 | 13 | 0.400 |
Why?
| Proctitis | 1 | 2012 | 6 | 0.390 |
Why?
| Herpes Genitalis | 1 | 2012 | 16 | 0.390 |
Why?
| H-2 Antigens | 1 | 2012 | 115 | 0.390 |
Why?
| Herpesvirus 2, Human | 1 | 2012 | 28 | 0.390 |
Why?
| Cellulitis | 1 | 2012 | 48 | 0.390 |
Why?
| Incidence | 3 | 2025 | 2614 | 0.380 |
Why?
| Isoxazoles | 1 | 2012 | 54 | 0.380 |
Why?
| Yellow Fever Vaccine | 2 | 2022 | 5 | 0.380 |
Why?
| Severe Dengue | 1 | 2011 | 10 | 0.380 |
Why?
| Herpesviridae Infections | 1 | 2013 | 134 | 0.380 |
Why?
| Acyclovir | 1 | 2012 | 99 | 0.370 |
Why?
| Healthcare Disparities | 3 | 2024 | 579 | 0.370 |
Why?
| Emigration and Immigration | 2 | 2022 | 50 | 0.370 |
Why?
| Animals | 15 | 2024 | 34487 | 0.360 |
Why?
| Treatment Outcome | 11 | 2024 | 10110 | 0.360 |
Why?
| B-Lymphocytes | 1 | 2016 | 812 | 0.350 |
Why?
| Poliovirus | 2 | 2022 | 82 | 0.350 |
Why?
| Pancreatitis | 1 | 2011 | 128 | 0.350 |
Why?
| Magnetic Resonance Imaging | 2 | 2019 | 3371 | 0.340 |
Why?
| Acute Lung Injury | 1 | 2013 | 264 | 0.330 |
Why?
| Moraxella | 1 | 2009 | 5 | 0.330 |
Why?
| Moraxellaceae Infections | 1 | 2009 | 3 | 0.330 |
Why?
| Lung Diseases | 2 | 2018 | 713 | 0.330 |
Why?
| Repressor Proteins | 1 | 2013 | 399 | 0.330 |
Why?
| Lupus Nephritis | 1 | 2009 | 49 | 0.320 |
Why?
| Databases, Factual | 2 | 2025 | 1264 | 0.320 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2023 | 2428 | 0.320 |
Why?
| Fluconazole | 3 | 2023 | 17 | 0.320 |
Why?
| Young Adult | 9 | 2024 | 12282 | 0.310 |
Why?
| Pulmonary Emphysema | 1 | 2011 | 244 | 0.310 |
Why?
| Biomarkers, Tumor | 1 | 2015 | 1175 | 0.310 |
Why?
| Aged, 80 and over | 5 | 2024 | 7029 | 0.310 |
Why?
| Arthritis, Infectious | 1 | 2009 | 57 | 0.310 |
Why?
| Presenilin-1 | 1 | 2008 | 31 | 0.300 |
Why?
| Fatal Outcome | 2 | 2019 | 299 | 0.290 |
Why?
| Immunoglobulin G | 3 | 2023 | 842 | 0.290 |
Why?
| Engineering | 1 | 2018 | 25 | 0.290 |
Why?
| Social Responsibility | 1 | 2018 | 47 | 0.290 |
Why?
| Staphylococcal Infections | 3 | 2023 | 386 | 0.280 |
Why?
| Echinocandins | 2 | 2023 | 7 | 0.270 |
Why?
| Mycobacterium | 2 | 2018 | 106 | 0.270 |
Why?
| Positron Emission Tomography Computed Tomography | 2 | 2018 | 84 | 0.270 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 1558 | 0.270 |
Why?
| Public Health | 3 | 2020 | 478 | 0.270 |
Why?
| Antiviral Agents | 1 | 2012 | 710 | 0.260 |
Why?
| Attitude | 1 | 2018 | 250 | 0.250 |
Why?
| HIV | 2 | 2018 | 225 | 0.250 |
Why?
| Sepsis | 2 | 2022 | 562 | 0.250 |
Why?
| Clinical Trials as Topic | 2 | 2020 | 997 | 0.250 |
Why?
| Electrocardiography | 2 | 2019 | 607 | 0.250 |
Why?
| Propensity Score | 2 | 2023 | 264 | 0.240 |
Why?
| Shock, Septic | 2 | 2021 | 207 | 0.240 |
Why?
| Acute Kidney Injury | 1 | 2013 | 777 | 0.240 |
Why?
| Clarithromycin | 1 | 2025 | 28 | 0.240 |
Why?
| Erythromycin | 1 | 2025 | 24 | 0.240 |
Why?
| Candida tropicalis | 1 | 2024 | 4 | 0.240 |
Why?
| Polymorphism, Genetic | 1 | 2008 | 638 | 0.240 |
Why?
| Cross Reactions | 1 | 2025 | 129 | 0.230 |
Why?
| Insect Bites and Stings | 1 | 2024 | 11 | 0.230 |
Why?
| Strongyloides stercoralis | 1 | 2024 | 2 | 0.230 |
Why?
| Azithromycin | 1 | 2025 | 91 | 0.230 |
Why?
| Colorado | 3 | 2020 | 4369 | 0.220 |
Why?
| Teicoplanin | 2 | 2023 | 15 | 0.220 |
Why?
| Peru | 2 | 2024 | 53 | 0.220 |
Why?
| World Health Organization | 2 | 2021 | 110 | 0.220 |
Why?
| Toxoplasmosis | 1 | 2023 | 36 | 0.220 |
Why?
| Anaphylaxis | 1 | 2025 | 98 | 0.210 |
Why?
| Toxoplasma | 1 | 2023 | 38 | 0.210 |
Why?
| Meningoencephalitis | 1 | 2023 | 25 | 0.210 |
Why?
| Alanine | 1 | 2024 | 141 | 0.210 |
Why?
| Voriconazole | 1 | 2023 | 20 | 0.210 |
Why?
| Rabies | 1 | 2022 | 1 | 0.210 |
Why?
| Rabies Vaccines | 1 | 2022 | 2 | 0.210 |
Why?
| Predictive Value of Tests | 2 | 2019 | 1934 | 0.210 |
Why?
| Antiparasitic Agents | 1 | 2022 | 3 | 0.200 |
Why?
| Glycopeptides | 1 | 2023 | 44 | 0.200 |
Why?
| Pyridones | 1 | 2024 | 158 | 0.200 |
Why?
| Students | 1 | 2018 | 570 | 0.200 |
Why?
| Tenofovir | 1 | 2024 | 231 | 0.200 |
Why?
| Kaplan-Meier Estimate | 1 | 2024 | 851 | 0.200 |
Why?
| Tomography, X-Ray Computed | 4 | 2019 | 2509 | 0.200 |
Why?
| Dog Diseases | 1 | 2022 | 52 | 0.200 |
Why?
| Americas | 1 | 2022 | 21 | 0.200 |
Why?
| Drug Therapy, Combination | 2 | 2018 | 1012 | 0.200 |
Why?
| Pregnancy | 4 | 2024 | 6355 | 0.200 |
Why?
| Prognosis | 3 | 2022 | 3766 | 0.200 |
Why?
| Sexually Transmitted Diseases | 1 | 2024 | 150 | 0.200 |
Why?
| Alzheimer Disease | 1 | 2008 | 515 | 0.200 |
Why?
| Disease Notification | 1 | 2022 | 12 | 0.190 |
Why?
| Italy | 1 | 2022 | 97 | 0.190 |
Why?
| Travel Medicine | 2 | 2020 | 5 | 0.190 |
Why?
| Staphylococcal Skin Infections | 2 | 2012 | 34 | 0.190 |
Why?
| Leprosy | 1 | 2021 | 21 | 0.190 |
Why?
| Rural Population | 2 | 2022 | 511 | 0.190 |
Why?
| Proportional Hazards Models | 1 | 2024 | 1194 | 0.190 |
Why?
| Acquired Immunodeficiency Syndrome | 1 | 2023 | 223 | 0.190 |
Why?
| Population Dynamics | 1 | 2022 | 136 | 0.180 |
Why?
| Leishmania guyanensis | 1 | 2020 | 1 | 0.180 |
Why?
| Case-Control Studies | 3 | 2018 | 3324 | 0.180 |
Why?
| Antiprotozoal Agents | 1 | 2020 | 13 | 0.180 |
Why?
| Leishmaniasis, Cutaneous | 1 | 2020 | 9 | 0.180 |
Why?
| Phosphorylcholine | 1 | 2020 | 18 | 0.180 |
Why?
| Personal Protective Equipment | 1 | 2021 | 50 | 0.170 |
Why?
| Pericarditis | 1 | 2020 | 11 | 0.170 |
Why?
| Anti-Inflammatory Agents | 1 | 2024 | 467 | 0.170 |
Why?
| Weight Gain | 1 | 2024 | 503 | 0.170 |
Why?
| Receptors, Interleukin-6 | 1 | 2020 | 37 | 0.170 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2022 | 1185 | 0.170 |
Why?
| Communicable Diseases, Emerging | 1 | 2020 | 30 | 0.170 |
Why?
| Africa | 1 | 2020 | 98 | 0.170 |
Why?
| Late Onset Disorders | 1 | 2019 | 1 | 0.170 |
Why?
| Immunization, Secondary | 1 | 2020 | 87 | 0.170 |
Why?
| Developing Countries | 1 | 2022 | 285 | 0.170 |
Why?
| Immunosuppressive Agents | 1 | 2024 | 682 | 0.170 |
Why?
| Bolivia | 1 | 2019 | 63 | 0.160 |
Why?
| Proteinuria | 1 | 2020 | 88 | 0.160 |
Why?
| Gram-Positive Bacterial Infections | 1 | 2020 | 65 | 0.160 |
Why?
| Infection Control | 1 | 2021 | 136 | 0.160 |
Why?
| Genetic Predisposition to Disease | 1 | 2008 | 2261 | 0.160 |
Why?
| Prospective Studies | 4 | 2023 | 7035 | 0.160 |
Why?
| Invasive Fungal Infections | 1 | 2019 | 10 | 0.160 |
Why?
| Sexual and Gender Minorities | 1 | 2022 | 193 | 0.160 |
Why?
| Amphotericin B | 1 | 2019 | 29 | 0.160 |
Why?
| Medical Errors | 1 | 2020 | 104 | 0.160 |
Why?
| Cryptococcus gattii | 1 | 2018 | 1 | 0.160 |
Why?
| Acute Disease | 2 | 2012 | 961 | 0.160 |
Why?
| Observational Studies as Topic | 1 | 2019 | 108 | 0.160 |
Why?
| Vulnerable Populations | 1 | 2020 | 157 | 0.160 |
Why?
| Dermatitis | 1 | 2018 | 19 | 0.160 |
Why?
| Speech Disorders | 1 | 2018 | 34 | 0.150 |
Why?
| Echocardiography | 2 | 2020 | 623 | 0.150 |
Why?
| Computed Tomography Angiography | 1 | 2019 | 115 | 0.150 |
Why?
| Africa, Western | 1 | 2018 | 17 | 0.150 |
Why?
| Stroke Volume | 1 | 2021 | 588 | 0.150 |
Why?
| Administration, Intravenous | 1 | 2019 | 137 | 0.150 |
Why?
| Emigrants and Immigrants | 1 | 2020 | 122 | 0.150 |
Why?
| Antibodies, Neutralizing | 1 | 2020 | 263 | 0.150 |
Why?
| Sex Factors | 1 | 2024 | 1942 | 0.150 |
Why?
| Raw Foods | 1 | 2018 | 2 | 0.150 |
Why?
| California | 1 | 2019 | 398 | 0.150 |
Why?
| Time Factors | 2 | 2019 | 6479 | 0.150 |
Why?
| Neoplasms | 1 | 2013 | 2460 | 0.150 |
Why?
| Ventricular Function, Left | 1 | 2021 | 524 | 0.150 |
Why?
| Administration, Oral | 2 | 2020 | 766 | 0.150 |
Why?
| Itraconazole | 1 | 2017 | 6 | 0.150 |
Why?
| Food Microbiology | 1 | 2018 | 58 | 0.140 |
Why?
| Respiration, Artificial | 1 | 2022 | 600 | 0.140 |
Why?
| Prisoners | 1 | 2020 | 141 | 0.140 |
Why?
| Arrhythmias, Cardiac | 1 | 2020 | 314 | 0.140 |
Why?
| Georgia | 1 | 2017 | 78 | 0.140 |
Why?
| Hyponatremia | 1 | 2018 | 40 | 0.140 |
Why?
| Longitudinal Studies | 2 | 2019 | 2706 | 0.140 |
Why?
| Cytokines | 2 | 2022 | 1984 | 0.140 |
Why?
| Disability Evaluation | 1 | 2019 | 285 | 0.140 |
Why?
| Patient Safety | 1 | 2020 | 286 | 0.140 |
Why?
| Research Design | 2 | 2021 | 1034 | 0.140 |
Why?
| Farmers | 1 | 2017 | 67 | 0.130 |
Why?
| Mebendazole | 1 | 2016 | 2 | 0.130 |
Why?
| Strongyloides | 1 | 2016 | 2 | 0.130 |
Why?
| Trichuris | 1 | 2016 | 3 | 0.130 |
Why?
| Antibodies, Viral | 1 | 2020 | 601 | 0.130 |
Why?
| Albendazole | 1 | 2016 | 5 | 0.130 |
Why?
| Arachis | 1 | 2017 | 108 | 0.130 |
Why?
| Ivermectin | 1 | 2016 | 13 | 0.130 |
Why?
| Patient Acceptance of Health Care | 1 | 2022 | 756 | 0.130 |
Why?
| Pharmacists | 1 | 2019 | 246 | 0.130 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 251 | 0.130 |
Why?
| Interleukin-6 | 1 | 2020 | 712 | 0.130 |
Why?
| Socioeconomic Factors | 2 | 2020 | 1211 | 0.130 |
Why?
| Hematocrit | 1 | 2016 | 93 | 0.130 |
Why?
| Evidence-Based Medicine | 1 | 2020 | 709 | 0.130 |
Why?
| Hospitals, University | 1 | 2016 | 176 | 0.130 |
Why?
| Vaccination | 2 | 2022 | 1343 | 0.130 |
Why?
| Brain | 1 | 2008 | 2615 | 0.130 |
Why?
| Praziquantel | 1 | 2015 | 5 | 0.130 |
Why?
| Anthelmintics | 1 | 2015 | 10 | 0.130 |
Why?
| Clone Cells | 1 | 2016 | 255 | 0.120 |
Why?
| Diagnosis, Differential | 1 | 2020 | 1408 | 0.120 |
Why?
| Disease Outbreaks | 3 | 2023 | 339 | 0.120 |
Why?
| Mental Disorders | 1 | 2023 | 1005 | 0.120 |
Why?
| Genotype | 2 | 2012 | 1828 | 0.120 |
Why?
| Recurrence | 1 | 2018 | 993 | 0.120 |
Why?
| Lipids | 1 | 2019 | 619 | 0.120 |
Why?
| Health Care Costs | 1 | 2018 | 366 | 0.120 |
Why?
| Academic Medical Centers | 1 | 2018 | 478 | 0.120 |
Why?
| Migraine Disorders | 1 | 2016 | 83 | 0.120 |
Why?
| Herpesvirus 4, Human | 1 | 2015 | 152 | 0.120 |
Why?
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 130 | 0.110 |
Why?
| Hearing Loss | 1 | 2018 | 210 | 0.110 |
Why?
| Frontal Lobe | 1 | 2015 | 153 | 0.110 |
Why?
| Adrenal Cortex Hormones | 1 | 2018 | 518 | 0.110 |
Why?
| Biopsy | 2 | 2020 | 1077 | 0.110 |
Why?
| Multivariate Analysis | 1 | 2018 | 1492 | 0.110 |
Why?
| Heart Transplantation | 1 | 2020 | 711 | 0.110 |
Why?
| Hemoglobins | 1 | 2016 | 336 | 0.110 |
Why?
| Delivery of Health Care | 1 | 2021 | 888 | 0.110 |
Why?
| Health Status Disparities | 3 | 2020 | 254 | 0.110 |
Why?
| Parasite Load | 1 | 2013 | 8 | 0.100 |
Why?
| Mycoplasma hominis | 1 | 2012 | 4 | 0.100 |
Why?
| Mycoplasma Infections | 1 | 2012 | 14 | 0.100 |
Why?
| APACHE | 1 | 2013 | 65 | 0.100 |
Why?
| Klebsiella Infections | 1 | 2013 | 23 | 0.100 |
Why?
| Intestines | 1 | 2016 | 344 | 0.100 |
Why?
| Platelet Count | 1 | 2013 | 82 | 0.100 |
Why?
| Disease Progression | 2 | 2012 | 2598 | 0.100 |
Why?
| Logistic Models | 1 | 2018 | 1975 | 0.100 |
Why?
| Molecular Typing | 1 | 2012 | 19 | 0.100 |
Why?
| Clindamycin | 1 | 2012 | 13 | 0.100 |
Why?
| Comorbidity | 2 | 2022 | 1537 | 0.100 |
Why?
| Feces | 1 | 2015 | 435 | 0.100 |
Why?
| Child | 6 | 2023 | 20636 | 0.100 |
Why?
| Serratia Infections | 1 | 2012 | 6 | 0.100 |
Why?
| Syncope | 1 | 2013 | 50 | 0.100 |
Why?
| Anti-HIV Agents | 2 | 2024 | 749 | 0.100 |
Why?
| Serratia marcescens | 1 | 2012 | 13 | 0.100 |
Why?
| Linkage Disequilibrium | 1 | 2013 | 256 | 0.100 |
Why?
| Central America | 2 | 2023 | 21 | 0.100 |
Why?
| Lymphoma, Non-Hodgkin | 1 | 2013 | 76 | 0.100 |
Why?
| Disease Eradication | 2 | 2022 | 4 | 0.100 |
Why?
| Mice, Inbred BALB C | 1 | 2015 | 1227 | 0.100 |
Why?
| Thoracic Vertebrae | 1 | 2012 | 74 | 0.090 |
Why?
| Hedgehog Proteins | 1 | 2013 | 187 | 0.090 |
Why?
| Viral Load | 2 | 2024 | 449 | 0.090 |
Why?
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2011 | 37 | 0.090 |
Why?
| Blister | 1 | 2011 | 40 | 0.090 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2015 | 504 | 0.090 |
Why?
| Microscopy | 1 | 2013 | 140 | 0.090 |
Why?
| Drug Resistance, Bacterial | 1 | 2012 | 170 | 0.090 |
Why?
| Drug Resistance, Viral | 1 | 2012 | 110 | 0.090 |
Why?
| Poliovirus Vaccine, Oral | 2 | 2022 | 25 | 0.090 |
Why?
| Soft Tissue Infections | 1 | 2011 | 35 | 0.090 |
Why?
| Venezuela | 2 | 2021 | 7 | 0.090 |
Why?
| Spinal Fractures | 1 | 2012 | 81 | 0.090 |
Why?
| Prevalence | 1 | 2018 | 2541 | 0.090 |
Why?
| Myocardium | 1 | 2016 | 967 | 0.090 |
Why?
| HIV Seropositivity | 1 | 2011 | 119 | 0.090 |
Why?
| Coinfection | 1 | 2012 | 131 | 0.090 |
Why?
| Cross Infection | 1 | 2013 | 199 | 0.090 |
Why?
| Urinary Tract Infections | 1 | 2012 | 144 | 0.090 |
Why?
| Gene Expression | 1 | 2015 | 1454 | 0.090 |
Why?
| Cross-Sectional Studies | 2 | 2019 | 5034 | 0.090 |
Why?
| Community-Acquired Infections | 1 | 2012 | 153 | 0.090 |
Why?
| Cohort Studies | 3 | 2022 | 5378 | 0.090 |
Why?
| Lupus Erythematosus, Systemic | 1 | 2013 | 244 | 0.080 |
Why?
| Penicillanic Acid | 1 | 2009 | 4 | 0.080 |
Why?
| Mice | 3 | 2023 | 16574 | 0.080 |
Why?
| Piperacillin | 1 | 2009 | 8 | 0.080 |
Why?
| Bacterial Typing Techniques | 1 | 2009 | 42 | 0.080 |
Why?
| Surgical Wound Infection | 1 | 2012 | 281 | 0.080 |
Why?
| Debridement | 1 | 2009 | 82 | 0.080 |
Why?
| Spinal Cord Injuries | 1 | 2012 | 191 | 0.080 |
Why?
| Anti-Infective Agents | 1 | 2011 | 243 | 0.080 |
Why?
| Hypertension | 1 | 2018 | 1234 | 0.080 |
Why?
| Infusions, Intravenous | 1 | 2009 | 390 | 0.080 |
Why?
| Needs Assessment | 2 | 2021 | 356 | 0.070 |
Why?
| Mortality | 2 | 2021 | 306 | 0.070 |
Why?
| Genes, Dominant | 1 | 2008 | 90 | 0.070 |
Why?
| Socialization | 1 | 2018 | 24 | 0.070 |
Why?
| Chromosome Disorders | 1 | 2008 | 39 | 0.070 |
Why?
| Global Health | 2 | 2020 | 327 | 0.070 |
Why?
| Point Mutation | 1 | 2008 | 221 | 0.070 |
Why?
| Amino Acid Substitution | 1 | 2008 | 280 | 0.070 |
Why?
| Genetic Markers | 1 | 2008 | 338 | 0.070 |
Why?
| DNA Mutational Analysis | 1 | 2008 | 384 | 0.070 |
Why?
| Pedigree | 1 | 2008 | 485 | 0.070 |
Why?
| Gene Frequency | 1 | 2008 | 504 | 0.070 |
Why?
| Intensive Care Units | 2 | 2023 | 734 | 0.070 |
Why?
| Chronic Disease | 1 | 2012 | 1690 | 0.060 |
Why?
| Wounds and Injuries | 1 | 2012 | 705 | 0.060 |
Why?
| Kidney Failure, Chronic | 1 | 2011 | 540 | 0.060 |
Why?
| Amyloid beta-Peptides | 1 | 2008 | 211 | 0.060 |
Why?
| Gene Expression Regulation | 1 | 2015 | 2508 | 0.060 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2013 | 2059 | 0.060 |
Why?
| Adenocarcinoma | 1 | 2012 | 888 | 0.060 |
Why?
| Genetic Testing | 1 | 2008 | 428 | 0.060 |
Why?
| Registries | 1 | 2013 | 1873 | 0.060 |
Why?
| Interviews as Topic | 1 | 2018 | 714 | 0.060 |
Why?
| Antivenins | 1 | 2024 | 35 | 0.060 |
Why?
| Prostatic Neoplasms | 1 | 2012 | 1011 | 0.060 |
Why?
| Mice, Inbred C57BL | 1 | 2015 | 5268 | 0.060 |
Why?
| Moths | 1 | 2024 | 38 | 0.060 |
Why?
| Aminobutyrates | 1 | 2024 | 33 | 0.060 |
Why?
| Drug Substitution | 1 | 2024 | 51 | 0.060 |
Why?
| Peptide Fragments | 1 | 2008 | 688 | 0.060 |
Why?
| Acetazolamide | 1 | 2023 | 24 | 0.050 |
Why?
| Antibodies, Protozoan | 1 | 2023 | 32 | 0.050 |
Why?
| Human Rights | 1 | 2023 | 18 | 0.050 |
Why?
| Seroepidemiologic Studies | 1 | 2023 | 155 | 0.050 |
Why?
| Adolescent | 4 | 2023 | 20158 | 0.050 |
Why?
| HIV Integrase Inhibitors | 1 | 2024 | 69 | 0.050 |
Why?
| Panama | 1 | 2022 | 11 | 0.050 |
Why?
| Yellow fever virus | 1 | 2022 | 3 | 0.050 |
Why?
| Medicine, Traditional | 1 | 2022 | 22 | 0.050 |
Why?
| Monkeypox virus | 1 | 2022 | 13 | 0.050 |
Why?
| Triazoles | 1 | 2024 | 150 | 0.050 |
Why?
| Standard of Care | 1 | 2023 | 72 | 0.050 |
Why?
| CD4 Lymphocyte Count | 1 | 2023 | 267 | 0.050 |
Why?
| Poliovirus Vaccine, Inactivated | 1 | 2022 | 28 | 0.050 |
Why?
| Cell Line | 1 | 2008 | 2736 | 0.050 |
Why?
| Immunoglobulin M | 1 | 2023 | 272 | 0.050 |
Why?
| Vancomycin | 1 | 2023 | 78 | 0.050 |
Why?
| Disease Models, Animal | 1 | 2012 | 3936 | 0.050 |
Why?
| Mexico | 1 | 2022 | 190 | 0.050 |
Why?
| Adenine | 1 | 2024 | 255 | 0.050 |
Why?
| Cameroon | 1 | 2021 | 8 | 0.050 |
Why?
| Cuba | 1 | 2021 | 11 | 0.050 |
Why?
| Mycobacterium leprae | 1 | 2021 | 8 | 0.050 |
Why?
| Contact Tracing | 1 | 2021 | 23 | 0.050 |
Why?
| Microbial Sensitivity Tests | 1 | 2023 | 348 | 0.050 |
Why?
| Healthy Volunteers | 1 | 2022 | 199 | 0.050 |
Why?
| Surveys and Questionnaires | 2 | 2019 | 5353 | 0.050 |
Why?
| Dogs | 1 | 2022 | 368 | 0.050 |
Why?
| Antineoplastic Agents | 1 | 2013 | 2041 | 0.050 |
Why?
| Curriculum | 1 | 2018 | 909 | 0.050 |
Why?
| Homosexuality, Male | 1 | 2022 | 175 | 0.050 |
Why?
| Minority Health | 1 | 2021 | 20 | 0.040 |
Why?
| Cardiovascular Infections | 1 | 2020 | 2 | 0.040 |
Why?
| Pericardiocentesis | 1 | 2020 | 10 | 0.040 |
Why?
| Meta-Analysis as Topic | 1 | 2021 | 169 | 0.040 |
Why?
| History, 17th Century | 1 | 2020 | 14 | 0.040 |
Why?
| Minority Groups | 1 | 2022 | 250 | 0.040 |
Why?
| Inflammation | 2 | 2022 | 2646 | 0.040 |
Why?
| Bone Diseases, Infectious | 1 | 2020 | 8 | 0.040 |
Why?
| Pregnancy Complications, Infectious | 1 | 2024 | 363 | 0.040 |
Why?
| Hemorrhage | 1 | 2024 | 643 | 0.040 |
Why?
| Social Justice | 1 | 2021 | 77 | 0.040 |
Why?
| Network Meta-Analysis | 1 | 2020 | 9 | 0.040 |
Why?
| Crowding | 1 | 2020 | 35 | 0.040 |
Why?
| Outpatients | 1 | 2023 | 366 | 0.040 |
Why?
| Communicable Disease Control | 1 | 2020 | 70 | 0.040 |
Why?
| Policy Making | 1 | 2020 | 87 | 0.040 |
Why?
| Catheter-Related Infections | 1 | 2020 | 67 | 0.040 |
Why?
| Brazil | 1 | 2020 | 154 | 0.040 |
Why?
| Signal Transduction | 1 | 2013 | 4812 | 0.040 |
Why?
| History, 21st Century | 1 | 2020 | 177 | 0.040 |
Why?
| Frail Elderly | 1 | 2020 | 121 | 0.040 |
Why?
| History, 20th Century | 1 | 2020 | 285 | 0.040 |
Why?
| Cough | 1 | 2020 | 115 | 0.040 |
Why?
| Staphylococcus aureus | 1 | 2023 | 434 | 0.040 |
Why?
| Southeastern United States | 1 | 2018 | 34 | 0.040 |
Why?
| Skilled Nursing Facilities | 1 | 2020 | 129 | 0.040 |
Why?
| Quality Assurance, Health Care | 1 | 2021 | 315 | 0.040 |
Why?
| Drug Compounding | 1 | 2019 | 96 | 0.040 |
Why?
| Social Determinants of Health | 1 | 2022 | 220 | 0.040 |
Why?
| Nursing Homes | 1 | 2020 | 154 | 0.040 |
Why?
| Immunization Schedule | 1 | 2020 | 196 | 0.040 |
Why?
| HIV-1 | 1 | 2024 | 833 | 0.040 |
Why?
| Immunologic Factors | 1 | 2020 | 227 | 0.040 |
Why?
| Residence Characteristics | 1 | 2020 | 324 | 0.040 |
Why?
| Risk | 1 | 2020 | 850 | 0.040 |
Why?
| Polymerase Chain Reaction | 1 | 2020 | 1020 | 0.040 |
Why?
| Critical Illness | 1 | 2023 | 755 | 0.030 |
Why?
| Organ Transplantation | 1 | 2020 | 218 | 0.030 |
Why?
| Urban Population | 1 | 2020 | 440 | 0.030 |
Why?
| Hospitals | 1 | 2022 | 631 | 0.030 |
Why?
| Models, Theoretical | 1 | 2020 | 541 | 0.030 |
Why?
| Occupational Exposure | 1 | 2020 | 299 | 0.030 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 754 | 0.030 |
Why?
| Mass Screening | 1 | 2022 | 1145 | 0.030 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2011 | 3625 | 0.030 |
Why?
| Electrophoresis, Gel, Pulsed-Field | 1 | 2012 | 19 | 0.030 |
Why?
| Molecular Epidemiology | 1 | 2012 | 63 | 0.020 |
Why?
| Risk Assessment | 1 | 2020 | 3223 | 0.020 |
Why?
| Infant | 1 | 2021 | 8912 | 0.020 |
Why?
| Lung | 1 | 2020 | 3745 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2011 | 1943 | 0.020 |
Why?
| Child, Preschool | 1 | 2021 | 10378 | 0.020 |
Why?
|
|
Henao Martinez's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|